FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095325458> ?p ?o ?g. }

• W2095325458 endingPage "325" @default.
• W2095325458 startingPage "322" @default.
• W2095325458 abstract "Background Acute asthma exacerbations can be life threatening and are recognizable to emergency medical service (EMS) personnel; however, the therapies and medications which these emergency service personnel can use to treat exacerbations are limited. Several studies have demonstrated the effective use of β2-agonist therapy in the treatment of patients complaining of wheezing or dyspnea, yet few EMS personnel can administer them. Objective The purpose of this study was to determine what therapeutic interventions emergency personnel around the state of New Mexico could use when responding to a call for a severe asthma exacerbation. Methods Questionnaires were distributed over a period of 3 years, 1992-1994, to all Emergency Service Agencies in New Mexico. Results Eighty percent of the emergency medical personnel administer oxygen to patients experiencing acute asthma exacerbations. Seventeen percent of EMS personnel administer epinephrine, 4% administer steroids, and only 23% administer β2 agonists. Only in more populated areas were EMS personnel allowed to administer β2 agonists, and those personnel had to have at least intermediate-level training. Most emergency response teams in the state consisted of EMT Basics and provided only basic life support services. In rural New Mexico, transport to a hospital can often take over one hour, which left EMS crews feeling helpless. Conclusions We conclude that due to the rural nature of New Mexico, EMS personnel should be trained in the use of β2 agonists and allowed to administer them to patients with acute asthma exacerbations. In addition, standard protocols for the pre-hospital management of acute asthma exacerbations should be instituted. Acute asthma exacerbations can be life threatening and are recognizable to emergency medical service (EMS) personnel; however, the therapies and medications which these emergency service personnel can use to treat exacerbations are limited. Several studies have demonstrated the effective use of β2-agonist therapy in the treatment of patients complaining of wheezing or dyspnea, yet few EMS personnel can administer them. The purpose of this study was to determine what therapeutic interventions emergency personnel around the state of New Mexico could use when responding to a call for a severe asthma exacerbation. Questionnaires were distributed over a period of 3 years, 1992-1994, to all Emergency Service Agencies in New Mexico. Eighty percent of the emergency medical personnel administer oxygen to patients experiencing acute asthma exacerbations. Seventeen percent of EMS personnel administer epinephrine, 4% administer steroids, and only 23% administer β2 agonists. Only in more populated areas were EMS personnel allowed to administer β2 agonists, and those personnel had to have at least intermediate-level training. Most emergency response teams in the state consisted of EMT Basics and provided only basic life support services. In rural New Mexico, transport to a hospital can often take over one hour, which left EMS crews feeling helpless. We conclude that due to the rural nature of New Mexico, EMS personnel should be trained in the use of β2 agonists and allowed to administer them to patients with acute asthma exacerbations. In addition, standard protocols for the pre-hospital management of acute asthma exacerbations should be instituted." @default.
• W2095325458 created "2016-06-24" @default.
• W2095325458 creator A5002717175 @default.
• W2095325458 creator A5008138486 @default.
• W2095325458 creator A5019608137 @default.
• W2095325458 creator A5024167144 @default.
• W2095325458 creator A5037799536 @default.
• W2095325458 date "1998-10-01" @default.
• W2095325458 modified "2023-10-14" @default.
• W2095325458 title "Prehospital Treatment of Acute Asthma in a Rural State" @default.
• W2095325458 cites W1966527361 @default.
• W2095325458 cites W1986103160 @default.
• W2095325458 cites W1993889997 @default.
• W2095325458 cites W2009132872 @default.
• W2095325458 cites W2040017152 @default.
• W2095325458 cites W2040231531 @default.
• W2095325458 cites W2042167765 @default.
• W2095325458 cites W2043984517 @default.
• W2095325458 cites W2057290660 @default.
• W2095325458 cites W2063223296 @default.
• W2095325458 cites W2076671766 @default.
• W2095325458 cites W2078379342 @default.
• W2095325458 cites W2080093885 @default.
• W2095325458 cites W2109446231 @default.
• W2095325458 cites W2122967020 @default.
• W2095325458 cites W2150401799 @default.
• W2095325458 cites W4233036048 @default.
• W2095325458 cites W4367337360 @default.
• W2095325458 doi "https://doi.org/10.1016/s1081-1206(10)63123-7" @default.
• W2095325458 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9809495" @default.
• W2095325458 hasPublicationYear "1998" @default.
• W2095325458 type Work @default.
• W2095325458 sameAs 2095325458 @default.
• W2095325458 citedByCount "15" @default.
• W2095325458 countsByYear W20953254582019 @default.
• W2095325458 countsByYear W20953254582022 @default.
• W2095325458 countsByYear W20953254582023 @default.
• W2095325458 crossrefType "journal-article" @default.
• W2095325458 hasAuthorship W2095325458A5002717175 @default.
• W2095325458 hasAuthorship W2095325458A5008138486 @default.
• W2095325458 hasAuthorship W2095325458A5019608137 @default.
• W2095325458 hasAuthorship W2095325458A5024167144 @default.
• W2095325458 hasAuthorship W2095325458A5037799536 @default.
• W2095325458 hasConcept C126322002 @default.
• W2095325458 hasConcept C159110408 @default.
• W2095325458 hasConcept C177713679 @default.
• W2095325458 hasConcept C194828623 @default.
• W2095325458 hasConcept C27415008 @default.
• W2095325458 hasConcept C2776042228 @default.
• W2095325458 hasConcept C2777014857 @default.
• W2095325458 hasConcept C2909082789 @default.
• W2095325458 hasConcept C545288138 @default.
• W2095325458 hasConcept C545542383 @default.
• W2095325458 hasConcept C71924100 @default.
• W2095325458 hasConceptScore W2095325458C126322002 @default.
• W2095325458 hasConceptScore W2095325458C159110408 @default.
• W2095325458 hasConceptScore W2095325458C177713679 @default.
• W2095325458 hasConceptScore W2095325458C194828623 @default.
• W2095325458 hasConceptScore W2095325458C27415008 @default.
• W2095325458 hasConceptScore W2095325458C2776042228 @default.
• W2095325458 hasConceptScore W2095325458C2777014857 @default.
• W2095325458 hasConceptScore W2095325458C2909082789 @default.
• W2095325458 hasConceptScore W2095325458C545288138 @default.
• W2095325458 hasConceptScore W2095325458C545542383 @default.
• W2095325458 hasConceptScore W2095325458C71924100 @default.
• W2095325458 hasIssue "4" @default.
• W2095325458 hasLocation W20953254581 @default.
• W2095325458 hasLocation W20953254582 @default.
• W2095325458 hasOpenAccess W2095325458 @default.
• W2095325458 hasPrimaryLocation W20953254581 @default.
• W2095325458 hasRelatedWork W1957770986 @default.
• W2095325458 hasRelatedWork W1985426726 @default.
• W2095325458 hasRelatedWork W1994339424 @default.
• W2095325458 hasRelatedWork W2098935330 @default.
• W2095325458 hasRelatedWork W2281005351 @default.
• W2095325458 hasRelatedWork W2320829605 @default.
• W2095325458 hasRelatedWork W2943761215 @default.
• W2095325458 hasRelatedWork W2962939929 @default.
• W2095325458 hasRelatedWork W4225925351 @default.
• W2095325458 hasRelatedWork W4313421893 @default.
• W2095325458 hasVolume "81" @default.
• W2095325458 isParatext "false" @default.
• W2095325458 isRetracted "false" @default.
• W2095325458 magId "2095325458" @default.
• W2095325458 workType "article" @default.